Prosecution Insights
Last updated: November 20, 2026

Tian Nmn Yu, USPTO Patent Examiner

Listed by the USPTO as YU, TIAN NMN

Tech Center 1600 • Art Units: 1634 1637 1656 1681 1682 1699

This examiner grants 56% of resolved cases

Analysis

YU, TIAN NMN is assigned to Tech Center 1600 and Art Unit 1634, with 92 resolved cases. The allowance rate is 56.5%, and the interview lift is 19.3%. The record provides a useful basis for prosecution planning, with the interview figure indicating a positive association that may support direct discussion of claim issues.

The median time to allowance is 1389 days. Applicants should account for that extended interval when managing filing, response, and continuation decisions. The listed companies are The Regents of the University of California, Guardant Health Inc., and Singular Genomics Systems Inc. The listed firms are HARNESS DICKEY (DETROIT), Sullivan & Worcester LLP, and WOLF GREENFIELD & SACKS, P.C. The figures should supplement, not replace, application-level analysis.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

56.5%
Allow Rate
-3.5% vs TC avg
169
Total Applications
+19.3%
Interview Lift
1389
Avg Prosecution Days
Based on 92 resolved cases, 2023–2026

Rejection Statute Breakdown

11.1%
§101 Eligibility
17.5%
§102 Novelty
31.0%
§103 Obviousness
30.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18620056 METHODS FOR EARLY DETECTION OF CANCER Non-Final OA GUARDANT HEALTH, INC.
18325759 COMPOSITIONS AND METHODS FOR ENRICHING METHYLATED POLYNUCLEOTIDES Non-Final OA GUARDANT HEALTH, INC.
18718585 Single-Cell Epigenomic Profiling Using Droplet Fluidics and Hydrogels Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18169681 EFFICIENT SCREENING LIBRARY PREPARATION Non-Final OA The Regents of the University of California
17625687 LIPID-MODIFIED OLIGONUCLEOTIDES AND METHODS OF USING THE SAME Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17928452 USE OF MICROVESICLE SIGNATURE FOR THE DIAGNOSIS AND TREATMENT OF KIDNEY TRANSPLANT REJECTION Non-Final OA The Brigham and Women's Hospital, Inc.
18704416 MANIPULATING AND DETECTING BIOLOGICAL SAMPLES Non-Final OA Singular Genomics Systems, Inc.
17531488 CONTACTLESS DETECTION OF AN ABERRANT CONDITION Non-Final OA Singular Genomics Systems, Inc.
18499328 DNA UNFOLDING USING A FREE-END TAG FLOW MODIFIER Non-Final OA Robert Bosch GmbH
19449295 DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS Final Rejection Natera, Inc.
18279006 METHODS FOR DETECTION OF DONOR-DERIVED CELL-FREE DNA IN TRANSPLANT RECIPIENTS OF MULTIPLE ORGANS Final Rejection Natera, Inc.
18038454 GRAPHENE-BASED BIOSENSOR AND DETECTION METHOD USING SAME Non-Final OA KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
17260611 POLYNUCLEOTIDE SYNTHESIS METHOD, KIT AND SYSTEM Final Rejection Oxford Nanopore Technologies PLC
18154592 RNA TEMPLATED LIGATION Non-Final OA 10x Genomics, Inc.
17438038 METHODS FOR USING SPATIAL ARRAYS FOR SINGLE CELL SEQUENCING Final Rejection 10x Genomics, Inc.
18570947 NUCLEIC ACID NANOPORE WITH ENHANCED SENSING FUNCTIONALITY Non-Final OA UCL BUSINESS LTD
18677551 ANALYSIS METHOD Non-Final OA Denso Corporation
18718373 BIOMARKERS TO DETECT AGGRESSIVE PROSTATE CANCER FROM INDOLENT FORMS AND TREATMENT THEREOF Non-Final OA The Johns Hopkins University
18666949 LINKAGE ASSAY Non-Final OA Bio-Rad Laboratories, Inc.
18631875 COMPOSITIONS AND METHODS FOR HLA HAPLOTYPE SEQUENCING Non-Final OA ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
18275797 MICRO RNA LIVER CANCER MARKERS AND USES THEREOF Non-Final OA THE CLEVELAND CLINIC FOUNDATION
17373653 cDNA SPIKE-IN CONTROL FOR SINGLE CELL ANALYSIS Non-Final OA Becton, Dickinson and Company
18361763 METHOD OF DETECTING MULTIPLE FORMS OF AN ANALYTE Final Rejection GEN-PROBE INCORPORATED
17619154 METHOD FOR DIAGNOSIS OF EARLY AGEING OF THE SKIN Non-Final OA L'OREAL
17349041 ASSESSING RISK WITH TOTAL CELL-FREE DNA Non-Final OA The Medical College of Wisconsin, Inc.
18678592 METHODS FOR DOUBLE-STRANDED SEQUENCING BY SYNTHESIS Non-Final OA ILLUMINA, INC.
18515013 REVERSIBLY CROSS-LINKED HYDROGELS, AND METHODS OF USING THE SAME FOR CLUSTER AMPLIFICATION Final Rejection Illumina, Inc.
18298631 METHODS AND COMPOSITIONS FOR RECOMBINASE-MEDIATED SELECTIVE CLEAVAGE OF NUCLEIC ACIDS Non-Final OA Illumina, Inc.
17285362 METHOD FOR MEASURING THE INFECTIVITY OF REPLICATION DEFECTIVE VIRAL VECTORS AND VIRUSES Final Rejection REGENXBIO Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Tian Nmn Yu's allowance rate?

56.5% of resolved applications examined by Tian Nmn Yu were allowed (92 resolved cases), compared with 30.2% across Art Unit 1634 over the last five years.

Does an interview help with examiner Tian Nmn Yu?

This examiner's interview lift is +19.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Tian Nmn Yu take to allow a patent?

Applications allowed by Tian Nmn Yu took 1,389 days on average from filing to allowance.

Which art unit does examiner Tian Nmn Yu work in?

Tian Nmn Yu examines applications in Art Unit 1634 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month